{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:26:41Z","timestamp":1787840801438,"version":"build-2784847793"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oncogenic pruritus or malignancy associated pruritus is an emerging cause of systemic pruritus in patients with malignancies. It is a debilitating condition and worsens the patient\u2019s quality of life, often interfering with their palliative care. Oncogenic pruritus can arise de-novo in such patients due to release of pruritogens and other inflammatory mediators from tumour cells into blood stream, or it may present as a component of paraneoplastic syndrome. A detailed history and clinical examination are necessary to rule out other causes of systemic pruritus. Objective evaluation of itch is recommended using various scales to evaluate the treatment response and assessing its severity. There is lack of clinical trials concerning the management of oncogenic pruritus and most information is derived from sporadic case reports. Despite being an important and emerging cause of pruritus during malignancy, this diagnosis is often missed and remains under-reported due to lack of awareness about this entity. This narrative review highlights the current understanding of this condition focusing on its causes, pathogenesis, diagnosis, and management, along with newer investigational drugs. These authors hope that the present review will generate awareness about this condition among treating physicians and enable its early diagnosis and appropriate management.<\/jats:p>","DOI":"10.4103\/ijd.ijd_523_24","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T02:00:06Z","timestamp":1749520806000},"page":"257-266","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Etiopathogenesis and Current Management of Oncogenic Pruritus - A Narrative Review"],"prefix":"10.4103","volume":"70","author":[{"given":"Sahana","family":"Srihari","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Poddar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Asansol District Hospital, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najeeba","family":"Riyaz","sequence":"additional","affiliation":[{"name":"Department of Dematology, KMCT Medical College, Calicut, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Praveen","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Dematology, Ramaiah Medical College, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Chigullapalli","sequence":"additional","affiliation":[{"name":"Dermatologist, Rajamahendravaram, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Shankar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Patna Medical College and Hospital, Patna, Bihar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Vyas","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Geetanjali Medical College and Hospital, Udaipur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raejesh","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Command Hospital, Panchkula, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhakar","family":"Sangolli","sequence":"additional","affiliation":[{"name":"Department of Dermatology, SSIMS and RC, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Mittal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, RNT Medical College and Hospital, Udaipur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrashis","family":"Podder","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine and Sagore Dutta Hospital, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"R1-20251031","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1053\/ctrv.2001.0231","article-title":"Pruritus in cancer patients","volume":"27","author":"Lidstone","year":"2001","journal-title":"Cancer Treatment Rev"},{"key":"R2-20251031","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ejp.760","article-title":"Malignancy-associated pruritus","volume":"20","author":"Rowe","year":"2016","journal-title":"Eur J Pain"},{"key":"R3-20251031","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jaad.2018.08.044","article-title":"Association between itch and cancer in 16,925 patients with pruritus:Experience at a tertiary care center","volume":"80","author":"Larson","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R4-20251031","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1365-4632.2007.03288.x","article-title":"Skin findings in internal malignant diseases","volume":"46","author":"Kili\u00e7","year":"2007","journal-title":"Int J Dermatol"},{"key":"R5-20251031","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jdermsci.2016.01.010","article-title":"Predictors of malignancy development in patients with chronic pruritus","volume":"82","author":"Fett","year":"2016","journal-title":"J Dermatol Sci"},{"key":"R6-20251031","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/hep.510290450","article-title":"The pruritus of cholestasis","volume":"29","author":"Jones","year":"1999","journal-title":"Hepatology"},{"key":"R7-20251031","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0923-1811(92)90059-K","article-title":"Some methods for evaluating clinical itch and their application for studying pathophysiological mechanisms","volume":"4","author":"Hagermark","year":"1992","journal-title":"J Dermatol Sci"},{"key":"R8-20251031","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1182\/blood-2008-09-179416","article-title":"Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders","volume":"113","author":"Ishii","year":"2009","journal-title":"Blood"},{"key":"R9-20251031","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2340\/00015555-1345","article-title":"Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma","volume":"92","author":"Ohmatsu","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"R10-20251031","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1038\/jid.2013.227","article-title":"IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus","volume":"133","author":"Singer","year":"2013","journal-title":"J Invest Dermatol"},{"key":"R11-20251031","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2340\/00015555-1958","article-title":"Il-31 does not correlate to pruritus related to early stage cutaneous T-cell lymphomas but is involved in pathogenesis of the disease","volume":"95","author":"Malek","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"R12-20251031","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","article-title":"IL-31:A new key player in dermatology and beyond","volume":"141","author":"Ba\u011fci","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R13-20251031","doi-asserted-by":"crossref","first-page":"111777","DOI":"10.1016\/j.intimp.2024.111777","article-title":"The relationship and clinical significance of serum cytokine expression level and skin pruritus in patients with Hodgkin lymphoma and angioimmunoblastic T-cell lymphoma","volume":"131","author":"Wen","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R14-20251031","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/jamadermatol.2014.895","article-title":"Association of pain and itch with depth of invasion and inflammatory cell constitution in skin cancer:Results of a large clinicopathologic study","volume":"150","author":"Yosipovitch","year":"2014","journal-title":"JAMA Dermatol"},{"key":"R15-20251031","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1189\/jlb.0404228","article-title":"Eosinophils function as antigen-presenting cells","volume":"76","author":"Shi","year":"2004","journal-title":"J Leukoc Biol"},{"key":"R16-20251031","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4065\/mcp.2010.0099","article-title":"Paraneoplastic syndromes:An approach to diagnosis and treatment","volume":"85","author":"Pelosof","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"R18-20251031","doi-asserted-by":"crossref","first-page":"e18125","DOI":"10.1111\/jcmm.18125","article-title":"Systemic inflammation and its relationship with pruritus in early-stage mycosis fungoides","volume":"28","author":"Solak","year":"2024","journal-title":"J Cell Mol Med"},{"key":"R19-20251031","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1001\/archdermatol.2012.3104","article-title":"Itch and pain in nonmelanoma skin cancer:Pain as an important feature of cutaneous squamous cell carcinoma","volume":"148","author":"Mills","year":"2012","journal-title":"Arch Dermatol"},{"key":"R20-20251031","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.critrevonc.2015.05.007","article-title":"Risk of pruritus in cancer patients treated with biological therapies:A systematic review and meta-analysis of clinical trials","volume":"96","author":"Santoni","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"R21-20251031","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","article-title":"The 5-D itch scale:A new measure of pruritus","volume":"162","author":"Elman","year":"2010","journal-title":"Br J Dermatol"},{"key":"R22-20251031","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2340\/00015555-3164","article-title":"European S2k guideline on chronic pruritus","volume":"99","author":"Weisshaar","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"R24-20251031","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"R25-20251031","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/dth.12027","article-title":"Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4","volume":"26","author":"Fischer","year":"2013","journal-title":"Dermatol Ther"},{"key":"R27-20251031","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1158\/1078-0432.CCR-21-0560","article-title":"Phase II open-label, single-arm trial to investigate the efficacy and safety of topical remetinostat gel in patients with basal cell carcinoma","volume":"27","author":"Kilgour","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R28-20251031","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1001\/jamadermatol.2021.4549","article-title":"Treatment of cutaneous squamous cell carcinoma with the topical histone deacetylase inhibitor remetinostat","volume":"158","author":"Kilgour","year":"2022","journal-title":"JAMA Dermatol"},{"key":"R29-20251031","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.det.2018.02.010","article-title":"Pruritus associated with targeted anticancer therapies and their management","volume":"36","author":"Wu","year":"2018","journal-title":"Dermatol Clin"},{"key":"R30-20251031","first-page":"121","article-title":"Paroxetine for pruritus in advanced cancer","volume":"16","author":"Zylicz","year":"1998","journal-title":"J Pain Symptom Manage"},{"key":"R31-20251031","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2011.12.021","article-title":"Pruritus in cutaneous T-cell lymphoma:A review","volume":"67","author":"Ahern","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R32-20251031","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/0269216319828189","article-title":"Does continuous subcutaneous infusion of lignocaine relieve intractable pruritus associated with advanced cutaneous T-cell lymphoma?A retrospective case series review","volume":"33","author":"Norris","year":"2019","journal-title":"Palliat Med"},{"key":"R33-20251031","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jaad.2006.04.025","article-title":"Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma","volume":"55","author":"Demierre","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R34-20251031","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jpainsymman.2006.07.006","article-title":"Efficacy of pregabalin in the management of cetuximab-related itch","volume":"32","author":"Porzio","year":"2006","journal-title":"J Pain Symptom Manage"},{"key":"R35-20251031","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2340\/00015555-1353","article-title":"Systemic kappa opioid receptor agonists in the treatment of chronic pruritus:A literature review","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"R36-20251031","doi-asserted-by":"crossref","first-page":"e10968","DOI":"10.1371\/journal.pone.0010968","article-title":"Targeting the neurokinin receptor 1 with aprepitant:A novel antipruritic strategy","volume":"5","author":"St\u00e4nder","year":"2010","journal-title":"PLoS One"},{"key":"R37-20251031","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/itx.0000000000000055","article-title":"A systematic review on the management of pruritus in patients with cutaneous T-cell lymphoma","volume":"6","author":"Farrah","year":"2021","journal-title":"Itch"},{"key":"R38-20251031","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/1346-8138.16289","article-title":"Current treatment strategies and emerging therapies for cutaneous lymphoma","volume":"49","author":"Yonekura","year":"2022","journal-title":"J Dermatol"},{"key":"R39-20251031","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0959-8049(21)00699-7","article-title":"Mode-of-action of HDAC inhibitor resminostat in CTCL","volume":"156","author":"Streubel","year":"2021","journal-title":"Eur J Cancer"},{"key":"R40-20251031","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.clml.2023.10.001","article-title":"Real-world treatment patterns and clinical outcomes with brentuximab vedotin or other standard therapies in patients with previously treated cutaneous T-cell lymphoma in the United States","volume":"24","author":"Barta","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R41-20251031","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"R42-20251031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2015.02.014","article-title":"Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities","volume":"158","author":"Cedeno-Laurent","year":"2015","journal-title":"Clin Immunol"},{"key":"R43-20251031","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3389\/fmed.2018.00333","article-title":"The antipruritic effect of phototherapy","volume":"5","author":"Legat","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"R44-20251031","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.abd.2021.03.001","article-title":"Phototherapy","volume":"96","author":"Barros","year":"2021","journal-title":"An Bras Dermatol"},{"key":"R45-20251031","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10103-017-2172-3","article-title":"Long-term effects of pulsed high-intensity laser therapy in the treatment of post-burn pruritus:A double-blind, placebo-controlled, randomized study","volume":"32","author":"Ebid","year":"2017","journal-title":"Lasers Med Sci"},{"key":"R46-20251031","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.21608\/ejhm.2020.115637","article-title":"Efficacy of low-level laser on renal pruritus in hemodialysis patients","volume":"81","author":"Emam","year":"2020","journal-title":"Egypt J Hosp Med"},{"key":"R47-20251031","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jphys.2023.10.010","article-title":"Massage, laser and shockwave therapy improve pain and scar pruritus after burns:A systematic review","volume":"70","author":"Santuzzi","year":"2024","journal-title":"J Physiother"},{"key":"R48-20251031","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/lsm.23313","article-title":"Fractional carbon dioxide laser is effective in amelioration of pruritus in primary cutaneous amyloidosis:A clinical and biochemical study","volume":"53","author":"Fawzi","year":"2021","journal-title":"Lasers Surg Med"},{"key":"R49-20251031","first-page":"13030\/qt9xp4640d","article-title":"Intractable prurigo nodularis successfully treated with combination therapy with a newly developed excimer laser and topical steroids","volume":"20","author":"Nakashima","year":"2014","journal-title":"Dermatol online J"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_523_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:29:16Z","timestamp":1787837356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_523_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_523_24","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2024-06-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}